Late-Breaking Science – Scientific Sessions 2024

Abstracts and presentations are embargoed for release until the date and time of presentation at Scientific Sessions 2025. Information may not be released before then. Failure to honor embargo policies will result in the trial being withdrawn on site and barred from presentation. Any breach of the embargo policy may adversely affect participation in future AHA Sessions. Clinical trial sponsors must comply with the embargo guidelines established by the American Heart Association.

In certain cases, a determination may be made that to fulfill the requirements of the U.S. Securities and Exchange Commission (SEC) or a corresponding regulatory organization in any country where that company's stock is traded, a publicly traded company, before the public release date, must disclose data or information from confidential abstracts. This is generally deemed necessary when it is considered probable that a reasonable investor in the company would regard such data or information as constituting a significant change to the totality of information provided to the investor. The abstract generally remains eligible to be included in AHA Scientific Sessions on the condition that the company, prior to the release, submits a letter to AHA signed by the company's General Counsel or other legal advisor. The letter must include the title of the abstract, specify the format/nature of the public disclosure, and state that the information must be publicly disclosed to comply with securities laws and that the information disclosed is the minimum necessary to be in compliance with these laws.

Please contact Mary Lu Hare if you are preparing a press release or for any questions.